CL2020003202A1 - Piridinil y pirazinil-(aza)indolsulfonamidas - Google Patents

Piridinil y pirazinil-(aza)indolsulfonamidas

Info

Publication number
CL2020003202A1
CL2020003202A1 CL2020003202A CL2020003202A CL2020003202A1 CL 2020003202 A1 CL2020003202 A1 CL 2020003202A1 CL 2020003202 A CL2020003202 A CL 2020003202A CL 2020003202 A CL2020003202 A CL 2020003202A CL 2020003202 A1 CL2020003202 A1 CL 2020003202A1
Authority
CL
Chile
Prior art keywords
indolesulfonamides
aza
pyridinyl
pyrazinyl
gpr17
Prior art date
Application number
CL2020003202A
Other languages
English (en)
Inventor
Christa E Mueller
Cécile Pegurier
Ali El-Tayeb
Joerg Hockemeyer
Marie Ledecq
Laurent Provins
Alvaro Cardenas
Nader Boshta
Mahmoud Rashed
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of CL2020003202A1 publication Critical patent/CL2020003202A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a piridinil y pirazinil-(aza)indolsulfonamidas que tienen actividad moduladora de GPR17. Los compuestos tienen utilidad en el tratamiento de una variedad de trastornos asociados con GPR17.
CL2020003202A 2018-06-19 2020-12-10 Piridinil y pirazinil-(aza)indolsulfonamidas CL2020003202A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18178429 2018-06-19
EP19157936 2019-02-19

Publications (1)

Publication Number Publication Date
CL2020003202A1 true CL2020003202A1 (es) 2021-05-07

Family

ID=67070797

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003202A CL2020003202A1 (es) 2018-06-19 2020-12-10 Piridinil y pirazinil-(aza)indolsulfonamidas

Country Status (26)

Country Link
US (1) US11939319B2 (es)
EP (2) EP4074703B1 (es)
JP (1) JP7382973B2 (es)
KR (1) KR102799157B1 (es)
CN (1) CN112469710B (es)
AU (1) AU2019289788B2 (es)
BR (1) BR112020025618A2 (es)
CA (1) CA3100795A1 (es)
CL (1) CL2020003202A1 (es)
DK (2) DK3810591T3 (es)
ES (2) ES2929992T3 (es)
FI (1) FI4074703T3 (es)
HR (2) HRP20221290T1 (es)
HU (2) HUE060128T2 (es)
IL (1) IL279428B2 (es)
LT (2) LT4074703T (es)
MX (1) MX2020012173A (es)
NZ (1) NZ771366A (es)
PL (2) PL4074703T3 (es)
PY (1) PY1947754A (es)
RS (2) RS63760B1 (es)
SG (1) SG11202012421TA (es)
SI (1) SI4074703T1 (es)
TW (1) TWI857957B (es)
UY (1) UY38266A (es)
WO (1) WO2019243303A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358875B2 (en) 2019-06-17 2025-07-15 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
EP4143303A4 (en) * 2020-05-01 2024-09-04 The Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR PROMOTING MYELINIZATION
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
AU2022227183A1 (en) * 2021-02-26 2023-06-22 F. Hoffmann-La Roche Ag Novel pyrimidin-2-yl sulfonamide derivatives
TW202313569A (zh) * 2021-06-04 2023-04-01 比利時商理溫醫療公司 吡咯基磺胺化合物
WO2024017857A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives
JP2025523939A (ja) 2022-07-20 2025-07-25 エフ. ホフマン-ラ ロシュ アーゲー 新規のナフチルおよびイソキノリンスルホンアミド誘導体
WO2024017855A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds
WO2024017856A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives
JP2025523899A (ja) 2022-07-20 2025-07-25 エフ. ホフマン-ラ ロシュ アーゲー 新規ピリミジニルおよびトリアジニルスルホンアミド誘導体
JP2025527937A (ja) * 2022-08-26 2025-08-25 エフ. ホフマン-ラ ロシュ アーゲー 新規重水素化ピリミジン-2-イルスルホンアミド誘導体
AU2023380534A1 (en) * 2022-11-20 2025-05-22 Myrobalan Therapeutics, Inc. Gpr17 modulators and uses thereof
WO2024115733A1 (en) * 2022-12-02 2024-06-06 Rewind Therapeutics Nv Fused pyrrolyl-sulfonamide compounds
WO2024153233A1 (en) * 2023-01-19 2024-07-25 Nanjing Immunophage Biotech Co., Ltd Compounds and their uses as gpr17 antagonists
CN116283748A (zh) * 2023-02-21 2023-06-23 康化(上海)新药研发有限公司 2,5-二氯-3-甲氧基吡啶的合成方法
GB2700773A (en) 2024-05-23 2026-03-11 Pheno Therapeutics Ltd Compounds
WO2025243044A1 (en) 2024-05-23 2025-11-27 Pheno Therapeutics Limited Compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
WO2005103291A1 (ja) 2004-04-27 2005-11-03 Takeda Pharmaceutical Company Limited Gタンパク質共役型レセプタータンパク質の新規リガンドとその用途
ITMI20042007A1 (it) * 2004-10-21 2005-01-21 Consiglio Nazionale Ricerche "modulatori del ricettore gpr17 e loro impieghi terapeutici"
WO2007094876A2 (en) 2005-12-20 2007-08-23 Teikoku Pharma Usa, Inc. Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same
DE112008002309A5 (de) 2007-06-25 2010-05-27 Acino Ag Elektrophoretisches transdermales Applikationssystem
US20110220151A1 (en) 2010-03-11 2011-09-15 Swinford Jerry L Method and Apparatus for Washing Downhole Tubulars and Equipment
IT1402549B1 (it) 2010-11-03 2013-09-13 Univ Pisa Composti e composizioni che modulano gpr17 e loro usi terapeutici e diagnostici
EP2567698B1 (en) * 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
KR20150008468A (ko) 2012-05-09 2015-01-22 폰다지오네 이탈리아나 스클레로시 멀티플라 - 에프아이에스엠 온러스 Gpr17 수용체 조절제
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ucb製藥有限公司 (氮雜)吲哚-和苯並呋喃-3-磺醯胺類

Also Published As

Publication number Publication date
CN112469710B (zh) 2024-05-14
EP4074703B1 (en) 2023-11-29
IL279428B2 (en) 2024-03-01
CN112469710A (zh) 2021-03-09
US20210206749A1 (en) 2021-07-08
PY1947754A (es) 2020-08-26
MX2020012173A (es) 2021-01-29
TWI857957B (zh) 2024-10-11
AU2019289788B2 (en) 2024-07-11
DK4074703T3 (da) 2024-01-29
KR102799157B1 (ko) 2025-04-21
AU2019289788A1 (en) 2021-01-21
FI4074703T3 (fi) 2024-02-01
TW202016088A (zh) 2020-05-01
US11939319B2 (en) 2024-03-26
HRP20221290T1 (hr) 2022-12-23
CA3100795A1 (en) 2019-12-26
JP2021527690A (ja) 2021-10-14
JP7382973B2 (ja) 2023-11-17
IL279428B1 (en) 2023-11-01
EP3810591B1 (en) 2022-08-10
HRP20240071T1 (hr) 2024-03-29
KR20210022675A (ko) 2021-03-03
PL4074703T3 (pl) 2024-05-13
NZ771366A (en) 2025-03-28
HUE060128T2 (hu) 2023-01-28
UY38266A (es) 2020-01-31
IL279428A (en) 2021-01-31
WO2019243303A1 (en) 2019-12-26
RS63760B1 (sr) 2022-12-30
SI4074703T1 (sl) 2024-03-29
ES2972491T3 (es) 2024-06-13
LT3810591T (lt) 2022-11-25
EP3810591A1 (en) 2021-04-28
BR112020025618A2 (pt) 2021-03-23
HUE065411T2 (hu) 2024-05-28
EP4074703A1 (en) 2022-10-19
LT4074703T (lt) 2024-02-26
DK3810591T3 (da) 2022-10-31
PL3810591T3 (pl) 2022-12-19
ES2929992T3 (es) 2022-12-05
SG11202012421TA (en) 2021-01-28
RS65272B1 (sr) 2024-03-29

Similar Documents

Publication Publication Date Title
CL2020003202A1 (es) Piridinil y pirazinil-(aza)indolsulfonamidas
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
CL2019001660A1 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
MX378273B (es) Compuestos activos hacia bromodominios.
CL2017001464A1 (es) Modulación inmunológica
MX2020012823A (es) Alcoxipiridinil indolsulfonamidas sustituidas.
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
MX2020008107A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
CY1117620T1 (el) Τριτοκαλινη για χρηση στην αντιμετωπιση της κυστικης ινωσης
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
MX2020001424A (es) Una composición para el cuidado personal.
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
CL2020000586A1 (es) Moduladores de la expresión de enac.
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina